Functioning gonadotropic adenoma
diseaseOn this page
Also known as functioning pituitary gonadotropic adenomagonadotroph adenoma
Summary
Functioning gonadotropic adenoma (MONDO:0019612) is a cancer and 2 clinical trials. Top therapeutic interventions include dexamethasone. A subtype of functioning pituitary gland adenoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Phenotypes (HPO): 34
- Clinical trials: 2
Clinical features
Signs & symptoms
Clinical features (HPO)
34 HPO clinical features (Orphanet curated; top 34 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0011759 | Pituitary gonadotropic cell adenoma | Obligate (100%) |
| HP:0000140 | Abnormality of the menstrual cycle | Frequent (30-79%) |
| HP:0000505 | Visual impairment | Frequent (30-79%) |
| HP:0000789 | Infertility | Frequent (30-79%) |
| HP:0000802 | Impotence | Frequent (30-79%) |
| HP:0000830 | Anterior hypopituitarism | Frequent (30-79%) |
| HP:0001123 | Visual field defect | Frequent (30-79%) |
| HP:0012378 | Fatigue | Frequent (30-79%) |
| HP:0030018 | Decreased female libido | Frequent (30-79%) |
| HP:0030088 | Increased serum testosterone level | Frequent (30-79%) |
| HP:0040086 | Abnormal prolactin level | Frequent (30-79%) |
| HP:0000138 | Ovarian cyst | Occasional (5-29%) |
| HP:0000141 | Amenorrhea | Occasional (5-29%) |
| HP:0000238 | Hydrocephalus | Occasional (5-29%) |
| HP:0000798 | Oligozoospermia | Occasional (5-29%) |
| HP:0000823 | Delayed puberty | Occasional (5-29%) |
| HP:0000824 | Decreased response to growth hormone stimulation test | Occasional (5-29%) |
| HP:0000837 | Increased circulating gonadotropin level | Occasional (5-29%) |
| HP:0000863 | Central diabetes insipidus | Occasional (5-29%) |
| HP:0000871 | Panhypopituitarism | Occasional (5-29%) |
| HP:0000938 | Osteopenia | Occasional (5-29%) |
| HP:0000939 | Osteoporosis | Occasional (5-29%) |
| HP:0001541 | Ascites | Occasional (5-29%) |
| HP:0002050 | Macroorchidism, postpubertal | Occasional (5-29%) |
| HP:0002315 | Headache | Occasional (5-29%) |
| HP:0002625 | Deep venous thrombosis | Occasional (5-29%) |
| HP:0002750 | Delayed skeletal maturation | Occasional (5-29%) |
| HP:0008236 | Isosexual precocious puberty | Occasional (5-29%) |
| HP:0008245 | Pituitary hypothyroidism | Occasional (5-29%) |
| HP:0008675 | Enlarged polycystic ovaries | Occasional (5-29%) |
| HP:0009888 | Abnormality of secondary sexual hair | Occasional (5-29%) |
| HP:0011748 | Adrenocorticotropic hormone deficiency | Occasional (5-29%) |
| HP:0012246 | Oculomotor nerve palsy | Occasional (5-29%) |
| HP:0100829 | Galactorrhea | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | functioning gonadotropic adenoma |
| Mondo ID | MONDO:0019612 |
| Orphanet | 91348 |
| NCIT | C45915 |
| SNOMED CT | 254960002 |
| UMLS | C0346304 |
| MedGen | 577353 |
| GARD | 0019158 |
| Is cancer (heuristic) | yes |
Also known as: functioning pituitary gonadotropic adenoma · gonadotroph adenoma
Disease family
This is a subtype of functioning pituitary gland adenoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › pituitary tumor › functioning pituitary gland neoplasm › functioning pituitary gland adenoma › functioning gonadotropic adenoma
Related subtypes (4): TSH producing pituitary tumor, Cushing disease due to pituitary adenoma, Nelson syndrome, mixed functioning pituitary adenoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00929669 | PHASE2 | TERMINATED | Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas |
| NCT01088763 | PHASE1 | TERMINATED | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXAMETHASONE | 4 | 1 |
Related Atlas pages
- Drugs: Dexamethasone